Ameriprise Financial Inc. lifted its stake in shares of Horizon Pharma PLC (NASDAQ:HZNP) by 419.1% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,127,694 shares of the biopharmaceutical company’s stock after acquiring an additional 1,717,841 shares during the quarter. Ameriprise Financial Inc. owned 1.30% of Horizon Pharma worth $26,979,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors also recently bought and sold shares of the company. Bank of Montreal Can increased its position in shares of Horizon Pharma by 16.3% during the second quarter. Bank of Montreal Can now owns 9,809 shares of the biopharmaceutical company’s stock worth $116,000 after acquiring an additional 1,378 shares during the period. Ballentine Partners LLC purchased a new stake in shares of Horizon Pharma during the second quarter worth $139,000. Sheaff Brock Investment Advisors LLC increased its position in shares of Horizon Pharma by 5.0% during the second quarter. Sheaff Brock Investment Advisors LLC now owns 10,500 shares of the biopharmaceutical company’s stock worth $125,000 after acquiring an additional 500 shares during the period. Family Management Corp purchased a new stake in shares of Horizon Pharma during the second quarter worth $131,000. Finally, Teacher Retirement System of Texas increased its position in shares of Horizon Pharma by 12.8% during the second quarter. Teacher Retirement System of Texas now owns 12,941 shares of the biopharmaceutical company’s stock worth $154,000 after acquiring an additional 1,466 shares during the period. 86.58% of the stock is currently owned by institutional investors and hedge funds.
A number of analysts have recently weighed in on HZNP shares. ValuEngine lowered Horizon Pharma from a “buy” rating to a “hold” rating in a research report on Friday, September 1st. Piper Jaffray Companies set a $18.00 price objective on Horizon Pharma and gave the stock a “buy” rating in a research report on Sunday, September 10th. Cantor Fitzgerald reissued a “buy” rating and issued a $17.00 target price on shares of Horizon Pharma in a report on Monday, September 11th. Jefferies Group reissued a “buy” rating and issued a $16.00 target price on shares of Horizon Pharma in a report on Wednesday, September 27th. Finally, Goldman Sachs Group initiated coverage on Horizon Pharma in a report on Thursday, September 28th. They issued a “buy” rating and a $16.00 target price on the stock. One research analyst has rated the stock with a sell rating, two have issued a hold rating and twelve have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $18.75.
Horizon Pharma (NASDAQ:HZNP) last issued its quarterly earnings data on Monday, November 6th. The biopharmaceutical company reported $0.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.22 by $0.04. The company had revenue of $271.60 million for the quarter, compared to analyst estimates of $259.74 million. Horizon Pharma had a positive return on equity of 20.22% and a negative net margin of 45.28%. The business’s quarterly revenue was up 30.1% compared to the same quarter last year. During the same quarter last year, the company posted $0.70 earnings per share. equities research analysts anticipate that Horizon Pharma PLC will post 0.72 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This report was posted by Week Herald and is the sole property of of Week Herald. If you are viewing this report on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The original version of this report can be read at https://weekherald.com/2017/12/30/horizon-pharma-plc-hznp-shares-bought-by-ameriprise-financial-inc.html.
Horizon Pharma Company Profile
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.